keyword
MENU ▼
Read by QxMD icon Read
search

Basal insulin dose

keyword
https://www.readbyqxmd.com/read/28108376/emodin-a-compound-with-putative-antidiabetic-potential-deteriorates-glucose-tolerance-in-rodents
#1
Sameer Abu Eid, Michael Adams, Thomas Scherer, Héctor Torres-Gómez, Martina Theresa Hackl, Mairam Kaplanian, Rainer Riedl, Anton Luger, Clemens Fürnsinn
Emodin is found in remedies from Traditional Chinese Medicine. Since antihyperglycaemic action was observed in rodents, non-scientific sources advertise emodin intake as a natural cure for diabetes. Emodin was admixed to high fat-food of obese mice at two doses (2 and 5g/kg; daily emodin uptake 103 and 229mg/kg). Comparison was made to ad libitum fed and to food restricted control groups, the latter showing the same weight gain as the corresponding emodin-treated groups. Emodin blunted food intake by 6% and 20% for the low and high dose, which was accompanied by proportionate reductions in weight gain...
January 17, 2017: European Journal of Pharmacology
https://www.readbyqxmd.com/read/28107204/non-invasive-blood-glucose-detection-system-based-on-conservation-of-energy-method
#2
Yang Zhang, Jian-Ming Zhu, Yong-Bo Liang, Hong-Bo Chen, Shi-Min Yin, Zhen-Cheng Chen
The most common method used for minimizing the occurrence of diabetes complications is frequent glucose testing to adjust the insulin dose. However, using blood glucose (BG) meters presents a risk of infection. It is of great importance to develop non-invasive BG detection techniques. To realize high-accuracy, low-cost and continuous glucose monitoring, we have developed a non-invasive BG detection system using a mixed signal processor 430 (MSP430) microcontroller. This method is based on the combination of the conservation-of-energy method with a sensor integration module, which collects physiological parameters, such as the blood oxygen saturation (SPO2), blood flow velocity and heart rate...
January 20, 2017: Physiological Measurement
https://www.readbyqxmd.com/read/28105735/observational-registry-of-basal-insulin-treatment-orbit-in-patients-with-type-2-diabetes-uncontrolled-with-oral-antihyperglycaemic-drugs-real-life-use-of-basal-insulin-in-china
#3
Linong Ji, Puhong Zhang, Dongshan Zhu, Xian Li, Jiachao Ji, Juming Lu, Xiaohui Guo, Weiping Jia, Jianping Weng, Yangfeng Wu, Wenying Yang, Dajin Zou, Zhiguang Zhou, Changyu Pan, Yan Gao, Satish K Garg
AIMS: To examine treatment patterns following basal insulin (BI) introduction in type 2 diabetes mellitus (T2DM) patients under real-world conditions across China. MATERIALS AND METHODS: Overall, 18,995 patients inadequately controlled [HbA1c ≥ 53 mmol/mol (7%)] with oral antihyperglycaemic drugs (OADs) and willing to receive BI treatment were registered at 209 hospitals and followed at baseline (visit 1), 3 months (visit 2), and 6 months (visit 3). Type of BI was initiated at physicians' discretion...
January 20, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28091878/insulin-degludec-in-clinical-practice-a-review-of-japanese-real-world-data
#4
Kohei Kaku, Michael Lyng Wolden, Jacob Hyllested-Winge, Emil Nørtoft
INTRODUCTION: In this literature review we evaluated the real-world clinical effectiveness of switching Japanese diabetic patients from their current insulin regimen to insulin degludec (IDeg). METHODS: Studies were identified from Japanese Diabetes Society (JDS) abstracts (2014-2015) and PubMed (2012 onwards). Inclusion criteria were: Japanese population, >15 participants, and studies switching patients from basal or basal-bolus insulin regimens to IDeg. Randomized controlled trials and case reports were excluded...
January 13, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/28058800/basal-rate-tests-24-h-fasts-performed-in-type-1-diabetic-subjects-with-either-absolute-fasting-or-snacks-containing-negligible-carbohydrate-amounts-result-in-similar-glucose-profiles-a-randomized-controlled-prospective-trial
#5
Maike Haase, Melanie Kahle, Martin Janert, Juris J Meier, Michael A Nauck
AIMS/HYPOTHESIS: Basal rate tests (24 h fasting periods) may be necessary to optimize basal insulin replacement in type 1 diabetes. It was the aim to prospectively compare allowing negligible carbohydrate snacks versus absolute fasting. METHODS: 20 patients with type 1 diabetes (age 48 ± 15 years; 9 women, 11 men; BMI 28.5 ± 4.5 kg/m(2) ; HbA1c 8.8 ± 2.0 % (73.0 ± 21.9 mmol/mol); insulin dose 0.69 ± 0.31 IU/kg body weight and day) participated in two basal rate tests lasting 24 h in random order with unchanged basal insulin replacement...
January 6, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28053550/real-world-medication-persistence-and-outcomes-associated-with-basal-insulin-and-glucagon-like-peptide-1-receptor-agonist-free-dose-combination-therapy-in-patients-with-type-2-diabetes-in-the-us
#6
Jay Lin, Melissa Lingohr-Smith, Tao Fan
BACKGROUND: Free-dose combination treatment with basal insulin and short-acting glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduces hyperglycemia via complementary targeting of fasting and postprandial blood glucose levels, however, in the real world, due to injection burden and clinical inertia, the full efficacy may not be able to translate into clinical and economic benefits. OBJECTIVE: The aim of the study was to evaluate treatment persistence and associated outcomes in patients with type 2 diabetes (T2D) treated with a GLP-1 RA in free-dose combination with basal insulin...
2017: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/28035840/cost-effectiveness-of-switching-to-insulin-degludec-from-other-basal-insulins-evidence-from-swedish-real-world-data
#7
Lena Landstedt-Hallin, Jens Gundgaard, Åsa Ericsson, Susanne Ellfors-Zetterlund
OBJECTIVES: Health economic analysis from a health care and societal point of view was conducted to assess cost-effectiveness of insulin degludec (IDeg) after switching from other basal insulins in people with type 1 diabetes. MATERIAL AND METHODS: This was a prospective, open-label, single arm, observational follow-up from August 2013-October 2015 of 476 consecutive patients at Danderyd Hospital [Stockholm, Sweden] who switched to IDeg from other basal insulins (99% basal insulin analogs)...
December 30, 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28025651/delphinidin-rich-maqui-berry-extract-delphinol%C3%A2-lowers-fasting-and-postprandial-glycemia-and-insulinemia-in-prediabetic-individuals-during-oral-glucose-tolerance-tests
#8
Jorge L Alvarado, Andrés Leschot, Álvaro Olivera-Nappa, Ana-María Salgado, Hernán Rioseco, Carolina Lyon, Pilar Vigil
Delphinidin anthocyanins have previously been associated with the inhibition of glucose absorption. Blood glucose lowering effects have been ascribed to maqui berry (Aristotelia chilensis) extracts in humans after boiled rice consumption. In this study, we aimed to explore whether a standardized delphinidin-rich extract from maqui berry (Delphinol) affects glucose metabolism in prediabetic humans based on glycemia and insulinemia curves obtained from an oral glucose tolerance test (OGTT) after a challenge with pure glucose...
2016: BioMed Research International
https://www.readbyqxmd.com/read/28008768/the-cost-effectiveness-of-dulaglutide-versus-liraglutide-for-the-treatment-of-type-2-diabetes-mellitus-in-spain-in-patients-with-bmi%C3%A2-30%C3%A2-kg-m-2
#9
Tatiana Dilla, Dimitra Alexiou, Ismini Chatzitheofilou, Ruba Ayyub, Julia Lowin, Kirsi Norrbacka
OBJECTIVE: Dulaglutide 1.5mg once weekly is a novel glucagon-like peptide 1 (GLP-1) receptor agonist, for the treatment of type two diabetes mellitus (T2DM). The objective was to estimate the cost-effectiveness of dulaglutide once weekly versus liraglutide 1.8mg once daily for the treatment of T2DM in Spain in patients with a BMI≥30 kg/m(2). METHODS: The IMS CORE Diabetes Model (CDM) was used to estimate costs and outcomes from the perspective of Spanish National Health System, capturing relevant direct medical costs over a lifetime time horizon...
December 23, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27999106/effects-of-13-hour-hyperglucagonemia-on-energy-expenditure-and-hepatic-glucose-production-in-humans
#10
Manu Chakravarthy, Stephanie Parsons, Michael E Lassman, Kristin Butterfield, Anita Y H Lee, Ying Chen, Stephen Previs, Jeffrey Spond, Shan Yang, Christopher Bock, Fanchao Yi, Jon Moon, Erica Wohlers-Kariesch, Steven R Smith, Christian Meyer
Glucagon (GCG) acutely stimulates energy expenditure (EE) and hepatic glucose production (HGP) in humans, but whether these effects persist during hyperglucagonemia of longer duration is unclear. Using a prospective, randomized, single-blind, crossover study design, we therefore measured EE and rates of glucose appearance (glucose RA) during three separate infusion protocols in healthy lean males: A) 10-h overnight GCG infusion (6 ng/[kg × min]) followed by 3-h infusion of GCG, octreotide (OCT), and insulin (INS) for basal replacement; B) overnight saline (SAL) infusion followed by GCG/OCT/INS infusion; and C) overnight SAL infusion followed by SAL/OCT/INS infusion...
January 2017: Diabetes
https://www.readbyqxmd.com/read/27995731/treatment-of-prednisolone-induced-hyperglycaemia-in-hospitalized-patients-insights-from-a-randomized-controlled-study
#11
Anjana Radhakutty, Jessica L Stranks, Brenda L Mangelsdorf, Sophie M Drake, Gregory W Roberts, Anthony T Zimmermann, Stephen N Stranks, Campbell H Thompson, Morton G Burt
AIMS: Prednisolone predominantly causes hyperglycaemia between midday and midnight. Consequently glargine-based basal-bolus insulin regimens may under-treat day-time hyperglycaemia and cause nocturnal hypoglycaemia. We investigated whether an isophane-based insulin regimen is safer and more effective than a glargine-based regimen in hospitalized patients. MATERIALS AND METHODS: 50 inpatients prescribed ≥20 mg/day prednisolone acutely with one finger prick blood glucose level (BGL) ≥15 mmol/L or two BGLs ≥10 mmol/L within 24 hours were randomised to either insulin isophane or glargine before breakfast and insulin aspart before meals...
December 20, 2016: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/27988180/factors-associated-with-reaching-or-not-reaching-target-hba1c-after-initiation-of-basal-or-premixed-insulin-in-patients-with-type-2-diabetes
#12
A J Scheen, H Schmitt, H H Jiang, T Ivanyi
AIMS: To evaluate factors associated with reaching or not reaching target glycated haemoglobin (HbA1c) levels by analysing the respective contributions of fasting hyperglycaemia (FHG), also referred to as basal hyperglycaemia, vs postprandial hyperglycaemia (PHG) before and after initiation of a basal or premixed insulin regimen in patients with type 2 diabetes. METHODS: This post-hoc analysis of insulin-naïve patients in the DURABLE study randomised to receive either insulin glargine or insulin lispro mix 25 evaluated the percentages of patients achieving a target HbA1c of <7...
December 14, 2016: Diabetes & Metabolism
https://www.readbyqxmd.com/read/27974167/lower-basal-insulin-dose-is-associated-with-better-control-in-type-1-diabetes
#13
David Strich, Lucy Balagour, Joelle Shenker, David Gillis
OBJECTIVE: To test the hypothesis that lower basal insulin doses may be paradoxically associated with better diabetic control, we assessed the association between the basal insulin dose and hemoglobin A1c (HbA1c) level in a group of children and young adults with type 1 diabetes. STUDY DESIGN: This was a retrospective study of 89 patients with type 1 diabetes (mean age, 14.67 ± 4.8 years; range, 3-29 years) treated in a single outpatient clinic. Forty-six of the 89 patients were treated with continuous subcutaneous insulin infusion, and the other 43 were treated with multiple daily injections (glargine as basal insulin)...
December 12, 2016: Journal of Pediatrics
https://www.readbyqxmd.com/read/27964837/efficacy-of-sitagliptin-for-the-hospital-management-of-general-medicine-and-surgery-patients-with-type-2-diabetes-sita-hospital-a-multicentre-prospective-open-label-non-inferiority-randomised-trial
#14
Francisco J Pasquel, Roma Gianchandani, Daniel J Rubin, Kathleen M Dungan, Isabel Anzola, Patricia C Gomez, Limin Peng, Israel Hodish, Tim Bodnar, David Wesorick, Vijay Balakrishnan, Kwame Osei, Guillermo E Umpierrez
BACKGROUND: The role of incretin-based drugs in the treatment of patients with type 2 diabetes admitted to hospital has not been extensively assessed. In this study, we compared the safety and efficacy of a dipeptidyl peptidase-4 inhibitor (sitagliptin) plus basal insulin with a basal-bolus insulin regimen for the management of patients with type 2 diabetes in general medicine and surgery in hospitals. METHODS: We did a multicentre, prospective, open-label, non-inferiority randomised clinical trial (Sita-Hospital) in five hospitals in the USA, enrolling patients aged 18-80 years with type 2 diabetes and a random blood glucose concentration of 7·8-22·2 mmol/L who were being treated with diet or oral antidiabetic drugs or had a total daily insulin dose of 0·6 units per kg or less, admitted to general medicine and surgery services...
December 7, 2016: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/27934653/leucine-and-mammalian-target-of-rapamycin-dependent-activation-of-muscle-protein-synthesis-in-aging
#15
REVIEW
Jean-Pascal De Bandt
The preservation or restoration of muscle mass is of prime importance for healthy aging. However, aging has been repeatedly shown to be associated with resistance of muscle to the anabolic effects of feeding. Leucine supplementation has been proposed as a possible strategy because of its regulatory role on protein homeostasis. Indeed, it acts independently of growth factors and leads to enhanced cap-dependent mRNA translation initiation and increased protein synthesis. Leucine acts as a signaling molecule directly at the muscle level via the activation of mammalian/mechanistic target of rapamycin complex 1 (mTORC1)...
December 2016: Journal of Nutrition
https://www.readbyqxmd.com/read/27930869/efficacy-and-safety-of-premixed-insulin-analogs-in-asian-patients-with-type-2-diabetes-a-systematic-review
#16
Wayne H-H Sheu, Linong Ji, Woo Je Lee, Abdul Jabbar, Jeong Hee Han, Thomas Lew
AIMS/INTRODUCTION: The primary aim of this systematic review was to provide an overview of the efficacy and safety of premixed insulin analogs in Asians, specifically East Asians, with type 2 diabetes. MATERIAL AND METHODS: The MEDLINE, Embase, Cochrane Library, and ClinicalTrials. gov databases were searched from 01 January 1995 to 26 November 2015. Randomized controlled trials involving East Asians with type 2 diabetes treated with any premixed insulin analog were included...
December 8, 2016: Journal of Diabetes Investigation
https://www.readbyqxmd.com/read/27918600/treatment-of-type-2-diabetes-with-biphasic-insulin-analogues
#17
Ali A Rizvi
The majority of patients with Type 2 diabetes require insulin therapy for treating hyperglycaemia. There are several regimens available for insulin initiation and maintenance. Insulin analogues have been developed to mimic normal physiology as closely as possible. Biphasic analogues can target both fasting and postprandial hyperglycaemia, with the added advantage of being premixed and thus convenient for the patient. A practical and feasible option is to initiate insulin with one or more biphasic preparations at mealtimes, thus providing both basal and prandial coverage...
2016: Eur Med J Diabetes
https://www.readbyqxmd.com/read/27888561/novel-hepato-preferential-basal-insulin-peglispro-bil-does-not-differentially-affect-insulin-sensitivity-compared-with-insulin-glargine-in-patients-with-type-1-and-type-2-diabetes
#18
Niels Porksen, Helle Linnebjerg, Parag Garhyan, Eric Chen Quin Lam, Mary Pat Knadler, Scott J Jacober, Ulrike Hoevelmann, Leona Plum-Moerschel, Elaine Watkins, Amalia Gastaldelli, Tim Heise
AIMS: Basal insulin peglispro (BIL) is a novel PEGylated basal insulin with a flat pharmacokinetic and glucodynamic profile and reduced peripheral effects, which results in a hepato-preferential action. In Phase 3 trials, patients with T1DM treated with BIL had lower prandial insulin requirements, yet improved prandial glucose control, relative to insulin glargine (GL). We hypothesized that this may be due to an enhanced sensitivity to prandial insulin with BIL resulting from lower chronic peripheral insulin action...
November 26, 2016: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/27871880/abscisic-acid-enhances-glucose-disposal-and-induces-brown-fat-activity-in-adipocytes-in-vitro-and-in-vivo
#19
Laura Sturla, Elena Mannino, Sonia Scarfì, Santina Bruzzone, Mirko Magnone, Giovanna Sociali, Valeria Booz, Lucrezia Guida, Tiziana Vigliarolo, Chiara Fresia, Laura Emionite, Ambra Buschiazzo, Cecilia Marini, Gianmario Sambuceti, Antonio De Flora, Elena Zocchi
Abscisic acid (ABA) is a plant hormone also present in animals, where it is involved in the regulation of innate immune cell function and of glucose disposal, through its receptor LANCL2. ABA stimulates glucose uptake by myocytes and pre-adipocytes in vitro and oral ABA improves glycemic control in rats and in healthy subjects. Here we investigated the role of the ABA/LANCL2 system in the regulation of glucose uptake and metabolism in adipocytes. Silencing of LANCL2 abrogated both the ABA- and insulin-induced increase of glucose transporter-4 expression and of glucose uptake in differentiated 3T3-L1 murine adipocytes; conversely, overexpression of LANCL2 enhanced basal, ABA- and insulin-stimulated glucose uptake...
February 2017: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/27860499/premixed-insulin-analogue-compared-with-basal-plus-regimen-for-inpatient-glycemic-control
#20
Abraham Edgar Gracia-Ramos, María Del Pilar Cruz-Domínguez, Eduardo Osiris Madrigal-Santillán, José Antonio Morales-González, Eduardo Madrigal-Bujaidar, José Leopoldo Aguilar-Faisal
BACKGROUND: No previous studies have investigated the use of a premixed insulin analogue in a hospital setting. OBJECTIVE: To compare the efficacy and safety of treatment with premixed insulin analogue (insulin lispro mix 75/25, LM75/25) with the basal-plus regimen with insulin glargine in hospitalized patients with type 2 diabetes (T2D). MATERIALS AND METHODS: A randomized clinical trial in hospitalized patients with T2D and glucose >140 mg/dL on admission was performed...
November 2016: Diabetes Technology & Therapeutics
keyword
keyword
32684
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"